Great businesses at fair prices — here's why each makes the list.
…and 242 more buy candidates in the full briefing.
22 name(s) sliding toward Avoid:
Value $100,393 ▲ +0.4% since 2026-07-16 · ▲ +$2,332 (+2.4%) since yesterday · S&P -1.9% · Cash $1,016
| Stock | Held | Price | Today | Since buy | Grade |
| DUOL | 77 sh | $132.82 | ▲ +8.7% | +3.0% | 90 |
| HIG | 73 sh | $140.14 | ▼ -0.3% | +2.6% | 90 |
| INTU | 33 sh | $303.91 | ▲ +2.6% | +3.1% | 88 |
| LOPE | 69 sh | $144.86 | ▲ +3.5% | +1.2% | 90 |
| META | 15 sh | $593.87 | ▼ -0.2% | -10.6% | 89 |
| NBIX | 58 sh | $176.41 | ▲ +0.4% | +2.8% | 89 |
| NEM | 110 sh | $93.47 | ▲ +0.3% | +2.9% | 86 |
| PRI | 31 sh | $314.71 | ▲ +0.0% | +0.6% | 92 |
| PTC | 78 sh | $125.21 | ▲ +10.8% | -1.7% | 89 |
| RMD | 49 sh | $203.08 | ▲ +4.0% | +0.2% | 89 |
Fictional money · prices update daily · a live test of whether the picks actually work.
Does the grading actually work? Two honest halves — a backtest on past data, and the real live record as it ripens. It reports the truth even when that's “not enough data yet.”
Reconstructed 319 graded moments across 150 companies (a sample of 150 names), then measured what each actually returned over the next 12 months.
Do higher grades earn better returns?
| Grade | Names | 12-mo return | vs S&P |
| A (80-100) | 43 | +13.5% | -0.5% |
| B (65-79) | 162 | +12.0% | -3.8% |
| C (50-64) | 90 | +15.2% | -0.2% |
| D-F (<50) | 24 | +41.0% | +27.2% |
→ higher grades did WORSE here (gap 27.5 pts) ⚠️
9 snapshot(s) since 2026-07-06, none ripe yet — first 6-month check ~2027-01-06.
Backtest limits: ~5 years back, surviving companies only, restated statements — a strong first read, not gospel. The live record is the hindsight-free gold standard and strengthens every month. Refreshed 2026-07-26. Educational only — not financial advice.
Hartford just reported Q2 earnings and the numbers were solid. EPS came in at $3.42, beating consensus by about 9%, and revenue of $5.23B grew nearly 7% year-over-year. The big standout: net investment income surged 22% to $800M, well above the $746M analysts expected. Personal insurance is turning around nicely (combined ratio improved from 94.1 to 90.1), and the company authorized a new $4.2B share buyback program — 27% bigger than the prior one. The one soft spot was employee benefits, where core earnings dropped 15% on higher disability losses, and business insurance's combined ratio ticked up to 91.4 from 87 due to catastrophe losses and less favorable prior-year development. They also announced the sale of Hartford Funds to Wellington Management to focus on core insurance. AM Best affirmed Hartford's credit ratings with a stable outlook. Grade stays high at 90 — the earnings support that.
Rough week for Duolingo — the stock dropped about 10% on a combination of AI disruption fears and management flagging slower growth ahead. The CEO said gross margins will fall to 69% by year-end as AI-related costs rise, and the company is prioritizing its ambitious 100M daily active user goal (by 2028) over short-term profitability. T-Mobile also announced an AI-powered translation feature that spooked investors. Shares are down 66% over the past year. However, a counterpoint: app analytics data from July shows Gen Z engagement is actually at its highest level since January 2025, and heavy users of Duolingo's AI chatbot are spending more time in the app, not less — suggesting AI is deepening the platform's stickiness rather than cannibalizing it. A separate Apptopia study also argued AI's threat to language-learning apps may be overstated. The grade (90) captures the strong underlying business (73% gross margins, 37% ROE, 41% revenue CAGR), but the stability pillar is the weakest (46) — reflecting the choppy margins and growth-stock volatility. Worth watching whether engagement trends hold.
Primerica hit an all-time high at $317.86 this past week. The news is mostly stock-price-driven (52-week high articles, a national survey about middle-income American budgets that's tangentially relevant to Primerica's customer base). Analyst consensus remains "Hold" from brokerages. No material negative catalysts. The grade at 92 reflects genuinely strong fundamentals — 32% ROE, P/E of 13, and 10.9% free cash flow yield — the numbers speak for themselves here.
All eyes are on Meta's Q2 earnings report this Wednesday (July 30). The stock has had 6 red days in a row and is down about 11% from its recent peak as investors get cautious ahead of results. WSJ reports Meta is fighting a "mountain of social-media lawsuits" — the timing is awkward right before earnings, though the article couldn't be fully read (WSJ paywall). The broader setup: this is the busiest earnings week of the quarter (Meta, Apple, Amazon, Microsoft all reporting, plus a Fed rate decision). Investors are watching whether Meta's massive AI spending is translating into ad revenue growth. The grade at 89 is supported by exceptional profitability (33% net margin, 82% gross margin) and growth (33% revenue YoY, 62% EPS YoY), though the valuation pillar (66) flags that at a P/E of 22 with only 1.7% FCF yield, some of this growth is already priced in.
PTC reports Q3 earnings tomorrow (July 29) after market close. The company is guiding for revenue of $580–640M and non-GAAP EPS of $1.24–$1.78. Consensus sits at $618M and $1.60 EPS. PTC has a track record of beating estimates (trailing 4-quarter average earnings surprise of 34.8%). The noteworthy product news: PTC launched "Onshape Labs," an early-access program bringing AI tools directly into its cloud-based CAD platform — AI Quick Render, automation agents, and AI-powered drawing validation. This differentiates PTC from legacy competitors like Siemens and Dassault by embedding AI into cloud-native workflows. Renaissance Technologies also disclosed buying 183,600 shares. The stock surged 5.6% on the day. Grade of 89 looks solid.
UBS maintained a Buy rating on ResMed but trimmed its price target from $312 to $300, citing a ventilator production issue (Astral ventilators have a field safety notice; manufacturing capacity is being redirected to replacements, constraining new sales). UBS cut its FY27 EPS estimate by ~1% because of this. Near-term Q4 results look strong though — 8.6% sales growth expected with improved gross margins. Importantly, UBS noted that cooling demand for sleep-apnea devices reflects market maturity, not GLP-1 drug competition (which was a big fear earlier). ResMed's free cash flow just hit a record $1.7B, and at 16.5x forward P/E, the stock looks reasonably priced. Worth watching the August 6 earnings report.
Neurocrine is gearing up for Q2 earnings. Consensus expects $2.26 EPS and $901M revenue, though the "Most Accurate Estimate" is lower at $2.08 — suggesting a possible miss. The big story: management reaffirmed full-year Ingrezza guidance of $2.7–2.8B (their flagship tardive dyskinesia drug). On the pipeline side, investors are watching Phase III direclidine (schizophrenia), osavampator (depression), and the recently acquired Vykat XR (Prader-Willi syndrome from the Soleno deal). The company also made leadership moves — hiring a new Chief Business Officer and promoting two executives. JPMorgan disclosed a 6.3% stake. Grade is strong at 89, though this is a name where earnings execution matters.
Federated Hermes reports earnings July 30. Consensus expects $1.19 EPS (+2.6% YoY) and $494M revenue (+16.3% YoY). The company has beaten EPS estimates in all four of the last quarters. As a major money market fund manager, FHI benefits from higher interest rates keeping money market fund yields attractive. Nothing dramatic in the news — institutional holders adjusting positions. Steady name.
Intuit is in a tough spot. The stock has fallen 64% over the past year as AI disruption fears mount. Major investors are bailing — Jensen Investment Management exited entirely, and Bristol Gate Capital liquidated its position, both citing concerns that generative AI directly threatens Intuit's moat of "guiding non-expert users through tax prep and bookkeeping." Management cut its full-year TurboTax outlook, announced a 17% workforce reduction, and non-GAAP operating margins contracted 132 bps despite rising R&D spend (up 19%). On the plus side, the grade at 88 reflects that the current numbers still look good, and the stock at $296 (down from $814) may be pricing in a lot of fear. But this is a name where the grade measures today's fundamentals while the market is pricing in tomorrow's disruption risk. Eyes open.
The stock hit a 52-week low at $135.61 — but the news flow is mostly institutional reshuffling (HSBC sold shares, BNY Mellon sold, KBC Group increased its position). No fundamental catalyst driving the decline. The grade at 90 captures a genuinely strong balance sheet (debt/equity 15%, current ratio 2.75) and exceptional stability (beta 0.57, steady margins), though growth is the weaker pillar (59). This looks like a case where the stock price and the fundamentals are diverging.
Weyerhaeuser reports Q2 earnings July 30. Analysts expect $0.08 EPS — a 33% year-over-year decline — on $1.79B revenue (down 4.7%). Earnings estimates have been revised downward, and the Zacks Rank is #4 (Sell). The stock has declined 22% over three years as the timber/lumber cycle weighs on results. At 43.5x P/E for a cyclical business earning $0.08 per quarter, the valuation is stretched. Raymond James remains bullish, but the consensus is cautious.
Starbucks reports Q3 earnings this week. Consensus expects $0.66 EPS. The "Back to Starbucks" turnaround strategy under the new CEO is focused on partner engagement and returning to the "third place" experience. Shares are up 23% year-to-date, which is a positive sign, but at 78.7x P/E — more than 3x the hospitality industry average — a lot of turnaround success is already priced in. Analysts see fair value at $106 vs the current ~$103, leaving only 3% upside. Key risk: whether the turnaround actually delivers comparable sales improvements, and execution of the Japan deal.
Quiet week — the main news is a quarterly dividend declaration (routine) and institutional position changes. The SEC 8-K filing couldn't be read (403 error). No material catalyst.
NNN REIT's stock crossed above its 200-day moving average, which is a mild technical positive. A Seeking Alpha Q2 preview called the outlook "solid but largely priced in." The news about Applebee's closing 35 underperforming locations could affect NNN as a net-lease REIT exposed to casual dining tenants — worth monitoring but not a direct hit.
Ormat presents a split picture: the DCF model suggests 47% undervaluation (implying ~$187/share vs $99), but at 47.9x P/E the stock is expensive by earnings standards (industry average is 16.4x). Free cash flow is currently negative (-$365M trailing), which undermines the premium valuation. The geothermal growth narrative depends on project execution. Migdal Insurance disclosed a 6% stake. This is one where the grade (48) and the valuation disconnect are both worth watching.
- WSJ article on Meta's lawsuits (paywall)
- SEC 8-K filing for TXNM Energy (403 forbidden)
- Several Google News redirect links returned only the SPA shell (known limit with Google News RSS URLs)
This is a once-a-morning read of free sources — research context, not financial advice. News is shown alongside the grade, never overriding it.
MarketMind is a personal, educational stock-research tool. Every morning it screens roughly 900 large- and mid-cap U.S. companies, grades each one from 0–100 on five research-backed pillars — financial health, profitability, growth, valuation, and moat — and surfaces the businesses that look strong and reasonably priced.
The idea it rests on: over the long run, a stock's price follows the company's profits. So rather than chasing hype, MarketMind looks for great businesses at fair prices and lets time do the work.
It also runs a Paper Fund — a fictional $100,000 that automatically follows the tool's own Buy ratings — so you can watch, over time, whether the picks actually work. It's pretend money: nothing here is ever bought or sold for real.
Built with free public data · refreshed every morning at 7:00 AM U.S. Central time.